中和抗体|达到两个100％！中和抗体治疗/预防新冠疾病均获突破( 二 )
我们预祝更多中和抗体疗法在治疗和预防COVID-19方面获得积极结果，在新冠疫苗之外，为抗击新冠疫情提供另一种强有力的工具 。
注：本文旨在介绍医药健康研究，不是治疗方案推荐 。如需获得治疗方案指导，请前往正规医院就诊 。
参考资料:
[1] New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent. Retrieved January 26, 2021, fromhttps://investor.lilly.com/news-releases/news-release-details/new-data-show-treatment-lillys-neutralizing-antibodies
[2] REGENERON REPORTS POSITIVE INTERIM DATA WITH REGEN-COV ANTIBODY COCKTAIL USED AS PASSIVE VACCINE TO PREVENT COVID-19. Retrieved January 26, 2021, from https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-positive-interim-data-regen-covtm-antibody
[3] COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials. Retrieved January 26, 2021, from https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html
[4] Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19. Retrieved January 26, 2021, from https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19
[5] COVID-19 therapies and vaccines: Clinical. Retrieved January 26, 2021, from https://www.biocentury.com/clinical-vaccines-and-therapies
[6] Yang et al, (2020) COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19, Antibody Therapeutics, tbaa020, https://doi.org/10.1093/abt/tbaa020
[7] SARS-CoV-2 Neutralizing Antibody Program Update. Retrieved January 26, 2021, from https://investor.lilly.com/static-files/081a5ef7-f5d6-4acc-b0d2-7ae4daf9e953
[8] Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19. Retrieved January 26, 2021, from https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-monoclonal-antibody-therapy-mild-moderate-covid-19.
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台 。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知 。
推荐阅读
- 人类免疫缺陷病毒|深港团队开发艾滋病新抗体：动物实验中能100％预防HIV
- 癌症|假如人得过一次癌症，会不会像其它病一样产生“抗体”？
- 月经|月经正常要达到的4个标准，多数女生都不知道，快查查是否符合
- 科兴疫苗|科兴疫苗加强针试验结果公布：抗体水平提高3-5倍
- 科兴|科兴第三针试验结果公布：抗体水平提高3-5倍
- 医生|怎样才能判断免疫力强弱？医生：能达到这4个标准的人，免疫力强
- amh|数值越低，越难怀孕！育龄女性的AMH值要达到多少？
- 抗体|打了新冠疫苗后是不是就有抗体？需要自测一下吗？权威解答来了！
- 抗体|打了新冠疫苗，到底要不要测抗体？最新研究来了！
- 疫情|科学家发现超级抗体，可免疫变异新冠病毒，或是终结疫情的关键？